DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years DBV Technologies (Euronext: DBV – ISIN: ...
DBV Technologies (ENXTPA:DBV) has scheduled a special call to unpack the VITESSE trial results and outline next steps for its Viaskin Peanut program, putting fresh attention on the company’s late ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results